ORKA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
62.1M
+24.0%
50.1M
+37.5%
36.4M
+5.8%
34.4M
+1.0%
34.1M
R&D
53.7M
+24.1%
43.3M
+48.4%
29.1M
+5.4%
27.6M
-4.7%
29.0M
SG&A
8.4M
+23.2%
6.8M
-6.0%
7.3M
+7.3%
6.8M
+32.7%
5.1M
Operating Income
-62136000
-24.0%
-50107000
-37.5%
-36434000
-5.8%
-34431000
-1.0%
-34105000
EBITDA
-62087000
-24.0%
-50064000
-37.6%
-36391000
-5.8%
-34403000
-0.9%
-34085000
Net Income
-49965000
-21.3%
-41206000
-29.5%
-31820000
-7.6%
-29583000
+2.3%
-30277000
EPS (Basic)
$-0.63
-14.5%
$-0.55
-14.6%
$-0.48
-9.1%
$-0.44
+20.0%
$-0.55
EPS (Diluted)
$-0.63
-14.5%
$-0.55
-14.6%
$-0.48
-9.1%
$-0.44
+20.0%
$-0.55
Shares (Diluted)
71.6M
+13.9%
62.9M
+14.0%
55.2M
+0.0%
55.2M
+25.2%
44.1M
Oruka Therapeutics (ORKA) — Financials